FOCUSING ON THOSE THAT CAN LEAST AFFORD TO LIVE
DEAD

Serial Number

85383540

Owner

Celgene Corporation

Attorney

Camille M. Miller

First Use Date

Mar 12, 2013

Filing Date

Jul 28, 2011

Add to watchlist:

No watchlists yet
View on USPTO

FOCUSING ON THOSE THAT CAN LEAST AFFORD TO LIVE Trademark

Serial Number: 85383540

FOCUSING ON THOSE THAT CAN LEAST AFFORD TO LIVE is a trademark filed by Celgene Corporation on July 28, 2011. The trademark is classified under Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

July 28, 2011

Registration Date

Not Registered

First Use Anywhere

March 12, 2013

First Use in Commerce

March 12, 2013

Published for Opposition

November 8, 2011

Goods & Services

Education services, namely, providing mentoring, tutoring, classes, seminars, and workshops in the fields of highlighting the advancements made in cancer treatments and discussing the importance of continuing research to develop innovative new treatments

Charitable fund raising services, namely, by providing individuals with the information and opportunity to make monetary donations to their favorite charity; charitable foundation services, namely, providing fund raising activities to support medical research and procedures for those in need; charitable fund raising services for sending underprivileged children to one of several camps around the United States which accept these children at discounted rates for one or more weeks; charitable fund raising services by means of an entertainment event; charitable fund raising services, namely, eleemosynary services in the field of collection, management, and disbursements of money in connection with programs and facilities for the welfare of children; financial services, namely, business fund raising provided over a computer network such as the Internet; charitable services, namely, providing financial assistance to patients and their families, charitable services, namely, providing funding to health care facilities and foundations of others for patients; providing project grants for environmental and health awareness projects; charitable services, namely, providing financial support to disadvantaged patients for the purpose of facilitating good health

Providing links to web sites of others featuring information about the diagnosis and treatment of cancer; providing on-line information in the field of diagnosis and treatment of cancer; providing an on-line computer database featuring information relating to diagnosis and treatment of cancer; providing medical information and pharmaceutical information services, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals

Development and testing services of new drugs and chemicals in the fields of biotechnology, chemistry and pharmaceuticals; providing an interactive web site that enables users to enter, access, track, monitor and generate health and medical information and reports; scientific study and research in the fields of the prevention, treatment and management of illness, health care delivery and the scientific aspects of health care policy, health care cost management and financing as these fields impact on quality of health care; research in the fields of chemicals and pharmaceuticals; research and testing services in the fields of chemicals and pharmaceuticals; research and development of new products for others in the fields of chemicals and pharmaceuticals; providing laboratory testing services, namely, gene sequencing-based tests and genotyping based on the assessment, development and application of genomic discoveries in the pharmaceutical, informatics and clinical diagnostic industries; scientific research services; scientific research, namely, development of pharmaceuticals or diagnostic methods for others; providing clinical trials

Filing History

ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Apr 14, 2014 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Apr 14, 2014 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 16, 2013 GNFN
FINAL REFUSAL E-MAILED
Sep 16, 2013 GNFR
SU - FINAL REFUSAL - WRITTEN
Sep 16, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 22, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 22, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 15, 2013 TROA
DATA MODIFICATION COMPLETED
Jun 12, 2013 DMCC
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 11, 2013 GNRN
NON-FINAL ACTION E-MAILED
Jun 11, 2013 GNRT
SU - NON-FINAL ACTION - WRITTEN
Jun 11, 2013 CNRT
STATEMENT OF USE PROCESSING COMPLETE
May 19, 2013 SUPC
USE AMENDMENT FILED
May 10, 2013 IUAF
TEAS STATEMENT OF USE RECEIVED
May 10, 2013 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 5, 2012 EXRA
SOU EXTENSION 2 GRANTED
Oct 4, 2012 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 4, 2012 AITU
SOU EXTENSION 2 FILED
Oct 2, 2012 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 2, 2012 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 12, 2012 EXRA
SOU EXTENSION 1 GRANTED
Jun 8, 2012 EX1G
SOU EXTENSION 1 FILED
Jun 8, 2012 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 8, 2012 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 3, 2012 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 8, 2011 NPUB
PUBLISHED FOR OPPOSITION
Nov 8, 2011 PUBO
LAW OFFICE PUBLICATION REVIEW COMPLETED
Sep 30, 2011 PREV
ASSIGNED TO LIE
Sep 27, 2011 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 27, 2011 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2011 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2011 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 23, 2011 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 17, 2011 GNRN
NON-FINAL ACTION E-MAILED
Sep 17, 2011 GNRT
NON-FINAL ACTION WRITTEN
Sep 17, 2011 CNRT
ASSIGNED TO EXAMINER
Sep 13, 2011 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 2, 2011 NWOS
NEW APPLICATION ENTERED
Aug 1, 2011 NWAP